Other
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform
Metabolomics-driven liquid biopsy platform expands from blood to urine, securing US IP while navigating a tight pre-revenue balance sheet.
Executive Summary
- BioMark Diagnostics received a USPTO Notice of Patent Allowance for a proprietary urine-based method to detect lung cancer.
- The allowed patent covers five distinct clinical and commercial applications: detection/diagnosis, staging, non-invasive population screening, treatment response assessment, and drug efficacy evaluation.
- The technology leverages clinical mass spectrometry and metabolomic profiling to identify early biochemical tumor changes via polyamine biomarkers in urine.
- This marks a strategic expansion from the company's validated blood-based liquid biopsy platform to a non-invasive alternative biological matrix.
- Management highlights the scalability of the MS-based urine test as a cost-effective alternative to traditional ctDNA sequencing workflows, which require tumor cell death and DNA shedding.
Material Impact
- The USPTO allowance strengthens BioMark's intellectual property moat in the United States, a critical jurisdiction for commercialization, reimbursement, and licensing.
- Expanding the diagnostic platform to urine broadens the addressable market and aligns with the industry shift toward non-invasive, multi-analyte screening.
- The announcement does not introduce new revenue streams, clinical trial results, or regulatory approvals in the near term. It is a procedural milestone that validates the underlying science but does not alter the company's immediate financial trajectory.
- Given the company's prior announcements regarding Asian patents and the HANSE trial, this US patent is an expected component of the broader IP strategy. The market likely already factored in continued patent filings as part of the standard development roadmap.
BUX · Price
Company Overview
- BioMark Diagnostics is a clinical-stage diagnostics company developing a liquid biopsy platform for early lung cancer detection.
- The core technology relies on metabolomics and clinical mass spectrometry to identify biochemical tumor changes, differentiating itself from traditional ctDNA sequencing methods.
- The company is expanding its platform from blood-based testing to urine-based screening, aiming to create a scalable, non-invasive diagnostic tool.
- Strategic focus includes securing global IP, validating the platform through large-scale clinical trials (e.g., HANSE), and pursuing regulatory accreditation for commercialization in North America and Europe.
More from BioMark Diagnostics Inc.
Jun 23, 2026 · 08:31